Amphetamine Mixed Salts (Adderall) Tablet Shortage: February 2026 Update
According to the U.S. Census Bureau's American Community Survey (ACS) 5-year estimates, the CDC PLACES population-level health analysis, and the CMS Hospital Compare quality data, Areazine publishes editorial articles drawing on more than 19,000 U.S. city profiles. See our methodology for full source attribution and refresh cadence.
The FDA reports ongoing supply disruptions for amphetamine mixed salts tablets, with several manufacturers experiencing limited availability or total stockouts through early 2026.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on February 11, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken — "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to — Drug Shortages — determines the regulatory framework behind it, which shapes what remedies (refunds, replacements, recalls, evacuations) are available to affected individuals and who holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to read it as a data point about the issuing system: how quickly FDA detected the hazard, how precise the geographic or product-identifier scope is, and whether similar notices have clustered in the same category or region in the last 90 days. Cluster patterns frequently precede a broader regulatory action — a single localized FDA drug-shortage notice is isolated; three of them within a quarter often indicate a supply-chain, infrastructure, or seasonal driver that will keep producing notices until something structural changes.
For decision-making, Areazine pairs each alert with the original agency URL, the full agency name, and a timestamp so you can verify the notice against the primary source before acting on it. Tags on this item (drug-shortage, fda, medication, Amphetamine) map to related alerts in the same area of risk — browsing them together gives a clearer picture than any single notice alone, because the shape of an ongoing issue only becomes visible across multiple sequential alerts.
What's in Shortage
The FDA has updated the status of the shortage involving Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, and Dextroamphetamine Sulfate Tablets. This medication, commonly known by the brand name Adderall, is a therapeutic agent used in the field of Psychiatry. The shortage affects various strengths of the tablet dosage form. While some presentations remain available, many manufacturers are reporting limited supplies or total unavailability.
Initial Posting Date: 10/12/2022
Last Updated: 02/04/2026
Which Manufacturers Are Affected
Supply status varies significantly by manufacturer and specific dosage strength:
Alvogen:
- Unavailable: 20mg (est. 2/20/2026), 30mg (est. 3/6/2026), and 5mg (est. 2/20/2026).
- Limited Availability: 15mg and 10mg (supporting contracted volume only).
- Contact: 844-842-8672 or CustomerService-US@alvogen.com
Elite Laboratories, Inc.:
- Limited Availability: 1.25mg, 7.5mg, 3.75mg, 1.875mg, 2.5mg, 3.125mg, and 5mg strengths (estimated 3-month duration).
- Contact: 888-852-6657
Teva Pharmaceuticals USA, Inc.:
- Available: Various strengths of Adderall and generic tablets (1.25mg, 2.5mg, 3.75mg, 1.875mg, 3.125mg).
- Limited Availability: 5mg (est. recovery Jan 2026), 7.5mg (est. recovery Feb 2026), and 3.75mg (est. recovery Feb 2026).
- Contact: 800-545-8800
Sandoz Inc.:
- Available: 1.25mg.
- Limited/Unavailable: 2.5mg, 5mg, and 7.5mg strengths are facing intermittent backorders in Q1 and early Q2 2026.
- Contact: 800-525-8747
SpecGx LLC:
- Available: 7.5mg, 5mg, 3.75mg, 1.25mg, 2.5mg, and 1.875mg strengths.
- Contact: 800-325-8888
Epic Pharma, LLC:
- Available: 2.5mg, 3.75mg, 5mg, and 1.25mg.
- Unavailable: 7.5mg (estimated availability in 2 weeks).
- Contact: (718) 276-8600 ext. 3
Lannett Company, Inc.:
- Available: 2.5mg, 1.875mg, 1.25mg, 7.5mg, 3.75mg, 3.125mg, and 5mg strengths.
- Contact: 844-834-0530
Why There's a Shortage
The FDA source data lists the reason for this ongoing shortage as "Other." No further specific details regarding manufacturing delays or demand increases were provided in the official database entry.
What Patients Should Do
If you are affected by this shortage, consider the following steps:
- Consult your pharmacist: They can check current stock for specific National Drug Codes (NDCs) and may know which manufacturers are currently delivering to their location.
- Contact your healthcare provider: Discuss the availability of different strengths or alternative treatment plans if your specific dosage is unavailable.
- Contact manufacturers: Use the contact information provided above to inquire about the most recent availability updates for your specific prescription.
Disclaimer: Patients should always consult with their healthcare provider or pharmacist regarding medication changes or treatment alternatives. Do not adjust your dosage without medical supervision.
Source
Data provided by the FDA Drug Shortage Database.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Frequently Asked Questions
Common questions about this FDA drug-shortage notice.
What is this FDA drug-shortage notice about? ▾
Which agency issued this alert? ▾
How severe is this alert? ▾
What area is affected? ▾
Where can I find more Drug Shortages updates? ▾
Primary source data
EPA Outdoor Air Quality Data
Federal monitoring network — every measurement we report
AirNow (EPA / NOAA)
Real-time AQI for every monitored U.S. location
National Weather Service
Active watches, warnings, and advisories — NOAA
CDC Air Quality & Health
Health-impact reference behind every AQI category